Why Illumina Stock Plummeted Today
Genomic sequencing specialist Illumina (ILMN -5.26%) was something of a victim in the U.S.-China trade spat on Tuesday. The government of the sprawling Asian nation placed the U.S. company on a blacklist, and given the size and power of that economy, investors weren't happy about the news.
Curious about Illumina (ILMN) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs
ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.
Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 12:00 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect. Good morning, everyone.
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database.
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.
Grail: What Lies Ahead After the Illumina Spin-Off
This spotlight on the ROBO Global Healthcare Technology and Innovation Index highlights Grail (GRAL), a standout within the Genomics subsector. It is a key component of the $53.6 million ROBO Global Healthcare Technology and Innovation ETF (HTEC).
